Trial Profile
Phase 2 Study of SGI-110 in Patients With Higher Risk MDS
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Guadecitabine (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 14 Nov 2023 Planned End Date changed from 1 Nov 2023 to 4 Nov 2024.
- 14 Nov 2023 Planned primary completion date changed from 1 Nov 2023 to 4 Nov 2024.
- 12 May 2023 Planned End Date changed from 1 Nov 2022 to 1 Nov 2023.